Baillie Gifford & Co
INSM icon

Baillie Gifford & Co’s Insmed INSM Stock Holding History

Baillie Gifford & Co’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-802
Closed -$13.7K – 367
2023
Q1 		$13.7K Buy
802
+95
+13% +$1.85K ﹤0.01% 375
2022
Q4 		$14.1K Hold
707
– – ﹤0.01% 380
2022
Q3 		$15K Hold
707
– – ﹤0.01% 368
2022
Q2 		$14K Hold
707
– – ﹤0.01% 375
2022
Q1 		$17K Hold
707
– – ﹤0.01% 384
2021
Q4 		$19K Hold
707
– – ﹤0.01% 384
2021
Q3 		$19K Sell
707
-80
-10% -$2.1K ﹤0.01% 378
2021
Q2 		$22K Hold
787
– – ﹤0.01% 348
2021
Q1 		$27K Buy
787
+27
+4% +$1.03K ﹤0.01% 310
2020
Q4 		$25K Buy
+760
New +$27.8K ﹤0.01% 307

Other funds holding INSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co's INSM Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Insmed (INSM) in Q2 2023, closing a stake of 802 shares — an estimated $13.7K sold.

Baillie Gifford & Co first reported a position in INSM in Q4 2020 and held it in 10 quarters. The position peaked at $27K in Q1 2021. 223 funds tracked by Wall St. Rank hold INSM as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Insmed position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 802 Insmed shares in Q2 2023, an estimated $13.7K.
  • Baillie Gifford & Co first reported a position in Insmed in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Insmed position peaked at $27K in Q1 2021.
  • 223 funds tracked by Wall St. Rank held Insmed as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.